TITLE

Pharma bankrolls academic institutes

AUTHOR(S)
Sinha, Gunjan
PUB. DATE
June 2012
SOURCE
Nature Biotechnology;Jun2012, Vol. 30 Issue 6, p474
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on the partnership between education institutes and pharmaceutical companies like Bristol-Myers Squibb Co. and Merck & Co. Inc.
ACCESSION #
76402983

 

Related Articles

  • Pharma: Other News To Note.  // BioWorld Today;4/23/2013, Vol. 24 Issue 77, p10 

    The article reports on Merck and Co. Inc.'s signing of a nonexclusive deal with Bristol-Myers Squibb Co. to conduct a Phase II trial of a once-daily oral combination regimen to treat chronic hepatitis C virus infection genotoype 1.

  • Merck, BMS drugs show progress in oncology. Zanki, Tom // njbiz;6/10/2013, p2 

    The article reports on clinical results presented by pharmaceutical firms Merck & Co. and Bristol-Myers Squibb about their experimental drugs that reduce tumor sizes in advanced melanoma patients during the American Society of Clinical Oncology's annual conference held from May 31 to June 4, 2013.

  • Top pharmaceutical companies. Barbarello // Business News New Jersey;11/29/99, Vol. 12 Issue 44, p21 

    Ranks the top pharmaceutical companies in New Jersey as of November 29, 1999 based on the number of employees. Includes Johnson and Johnson Co.; Merck and Co. Inc.; Bristol-Myers Squibb Co.

  • New generic launches buoy growth.  // Drug Store News;9/25/2006, Vol. 28 Issue 12, p26 

    The article reports on the expiration of patent licenses of major brand-name drugs which experts say the beginning of patent expirations of branded drugs spanning for 5 years in the U.S. Three of the major brand name drugs who lost its patent protection included Zocor manufactured by Merck...

  • New molecular entities.  // Formulary;Dec2007, Vol. 42 Issue 12, p661 

    The article evaluates the two therapeutic drugs the Raltegravir from Merck & Co., Inc., and the Ixabepilone from Bristol-Myers Squibb Co.

  • 3 bargain stocks to grab and hold. Altfest, Lewis J. // Medical Economics;7/26/2002, Vol. 79 Issue 14, p18 

    Provides information on several pharmaceutical companies in which the return of investment has a 50 percent potential. Bristol-Myers Squibb; Merck & Co.; Schering-Plough.

  • STOCK SCREENS.  // Dow Theory Forecasts;8/20/2001, Vol. 57 Issue 34, p7 

    Reports on buying opportunities in the pharmaceutical industry as of August 20, 2001. Decline in Dow Jones Pharmaceutical Index; Factors attributed to doubts over the prospects of the industry; Problems besetting companies including Bristol-Myers Squibb, Merck and Eli Lilly.

  • TOP PHARMACEUTICAL COMPANIES. Diefenderfer, Jim // Business News New Jersey;11/28/2000, Vol. 13 Issue 48, p23 

    Ranks the top 45 pharmaceutical companies in New Jersey based on the number of local employees. Johnson & Johnson; Merck & Co.; Bristol-Myers Squibb.

  • Pharmaceutical Companies.  // njbiz;2004 Book of Lists, Vol. 17 Issue 27, p133 

    Presents a list of pharmaceutical companies ranked by number of employees in New Jersey as of July 2004. Johnson & Johnson; Bristol-Myers Squibb; Merck.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics